Kernal Biologics Analysis: $11M Raised
What is Kernal Biologics?
Kernal Biologics develops mRNA-based therapeutics for targeted treatments in oncology and immunology using their innovative mRNA 2.0 platform.
Employees
20
Founded
2016
Revenue
$0.6M
Business Model
Licensing proprietary mRNA technology and partnerships for drug development funding.
Investors
- Amgen
Product Features & Capabilities
- mRNA 2.0 platform, selectively delivered mRNA, precise targeting, therapeutic applications in oncology and immunology, onco-selective mRNA therapeutics, KR-335 immuno-oncology candidate, pipeline of mRNA therapies.
How much Kernal Biologics raised
Seed - $10.5 million
July 22, 2021Lead Investor: Hummingbird Ventures, Amgen
Who are the founders of Kernal Biologics
Market Focus
Kernal Biologics primarily focuses on the biotechnology industry, specifically developing mRNA-based therapies for oncology and immunology.
Competitors Overview
Kernal Biologics operates in the mRNA therapeutics market, focusing on oncology and immunology. Its main competitors include:
- Strand Therapeutics: This company designs genetic circuits and small-molecule chemical inducers for precise control of therapeutic activities. They focus on self-ampl
See something that needs updating? Suggest edits to this profile.